KYODO NEWS IMAGELINK

報道写真の購入なら共同通信イメージズ

  • 偽薬
  • うそ
  • 安全性
  • 新型肺炎
  • 販売
  • しん
  • せき
  • アメリカ
  • シノファーム
  • データ

「プラセボ」の写真・映像

絞り込み
  • 提供元
  • 日付
  • 種類
  • 向き
  • カテゴリ
並び順
  • 古い順
30
( 1 30 件を表示)
  • 1
30
( 1 30 件を表示)
絞り込み
並び順
  • 古い順
  • 2019年08月25日
    Charity football game “Kicken mit Herz“ (Kicking with heart)

    25 August 2019, Hamburg: Sigmar Gabriel (SPD, l), former Foreign Minister and SPD Chairman, hands over the winner‘s trophy to Thomas Mir, Deputy Director of the University Cardiovascular Centre UKE Hamburg and initiator of “Kicken mit Herz“ and his team, the Placebo Kickers, at the charity football game “Kicken mit Herz“ in the Hoheluft stadium. Photo: Christian Charisius/dpa、クレジット:DPA/共同通信イメージズ

    商品コード: 2019082700091

  • 2019年08月25日
    Charity football game “Kicken mit Herz“ (Kicking with heart)

    25 August 2019, Hamburg: The winner‘s trophy of the charity football game “Kicken mit Herz“ (Kicking with Heart) will be awarded after the match between the Hamburg Allstars and the Placebo Kickers on the grass in the Hoheluft stadium. Photo: Christian Charisius/dpa、クレジット:DPA/共同通信イメージズ

    商品コード: 2019082700146

  • 2019年08月25日
    Charity football game “Kicken mit Herz“ (Kicking with heart)

    25 August 2019, Hamburg: The winner‘s trophy of the charity football game “Kicken mit Herz“ (Kicking with Heart) will be awarded after the match between the Hamburg Allstars and the Placebo Kickers on the grass in the Hoheluft stadium. Photo: Christian Charisius/dpa、クレジット:DPA/共同通信イメージズ

    商品コード: 2019082700080

  • 2019年12月19日
    水口直樹社長 優しいうそで薬減らそう

    偽薬「プラセプラス」を販売するプラセボ製薬の水口直樹社長

    商品コード: 2019121901069

  • 2019年12月19日
    偽薬「プラセプラス」 優しいうそで薬減らそう

    プラセボ製薬が販売する偽薬「プラセプラス」

    商品コード: 2019121901071

  • 01:20.28
    2020年06月25日
    「新華社」中国開発の新型コロナ不活化ワクチン、臨床試験進む

    中国医薬集団(シノファーム)傘下の武漢生物製品研究所が開発した新型コロナウイルス不活化ワクチンの第1・2相臨床試験盲検下レビューと段階的盲検化解除の結果がこのほど発表された。それによると、ワクチン接種後の安全性は高く、深刻な副作用は1件も生じなかった。異なる手順や用量のワクチンを接種した被験者には、いずれも高力価の抗体ができており、28日の間隔を空けて2回目の接種をした後は、中和抗体の陽転率が100%に達した。同研究所首席科学者の申碩(しん・せき)氏は、有効性を示す重要な指標は中和抗体の陽転率と力価レベルだと指摘。これまでのワクチン開発の経験から、中和抗体の高い陽転率と高力価が維持できれば、ワクチンは非常に高い確率で成功するので、今回の臨床試験は重要な段階的成果を収めたとの見方を示した。同研究所によると、今回の臨床試験は、ランダム・二重盲検・プラセボ対照の第1・2相試験で、河南省疾病予防控制センターの主導の下、4月12日に同省武陟県で始まった。現時点の被験者は1120人で、既に全員が2回の接種を終えた。申氏は、科学的観点から最終的なワクチン有効率は実際の臨床研究によって決定すべきだと説明。全ては第3相臨床研究の進展にかかっており、この点に対し自信を持っていると述べた。(記者/廖君、潘志偉)<映像内容>新型コロナウイルス不活化ワクチンの開発、撮影日:撮影日不明、クレジット:新華社/共同通信イメージズ

    商品コード: 2020062804967

  • 2020年08月25日
    Covid-19 Vaccine testing begins in U.S.

    August 25, 2020, Atlanta, GA, USA: Volunteers selected to participate in blind Phase 2 and 3 clinical trials for Covid-19 vaccines are injected with either a placebo saline solution or one of two vaccines being evaluated for safety, tolerability, immunogenicity and efficacy in protection against Covid-19 in healthy adults. .The trials, expected to enroll 30,000 healthy adults, are being conducted in several cities in the U.S. After injected with the vaccine, participants are given a self-swab kit to be used in they develop an illness. The trials are conducted by Pfizer Corp for BioNTech, Inc.The vaccines do not contain the whole Coronavirus, or parts of the virus than can make people ill, according to the test’s informed consent form. (Credit Image: © Robin Rayne/ZUMA Wire)、クレジット:©Robin Rayne/ZUMA Wire/共同通信イメージズ

    商品コード: 2020082704529

  • 2020年08月25日
    Covid-19 Vaccine testing begins in U.S.

    August 25, 2020, Atlanta, GA, USA: Volunteers selected to participate in blind Phase 2 and 3 clinical trials for Covid-19 vaccines are injected with either a placebo saline solution or one of two vaccines being evaluated for safety, tolerability, immunogenicity and efficacy in protection against Covid-19 in healthy adults. .The trials, expected to enroll 30,000 healthy adults, are being conducted in several cities in the U.S. After injected with the vaccine, participants are given a self-swab kit to be used in they develop an illness. The trials are conducted by Pfizer Corp for BioNTech, Inc.The vaccines do not contain the whole Coronavirus, or parts of the virus than can make people ill, according to the test’s informed consent form. (Credit Image: © Robin Rayne/ZUMA Wire)、クレジット:©Robin Rayne/ZUMA Wire/共同通信イメージズ

    商品コード: 2020082704725

  • 2020年08月25日
    Covid-19 Vaccine testing begins in U.S.

    August 25, 2020, Atlanta, GA, USA: Volunteers selected to participate in blind Phase 2 and 3 clinical trials for Covid-19 vaccines are injected with either a placebo saline solution or one of two vaccines being evaluated for safety, tolerability, immunogenicity and efficacy in protection against Covid-19 in healthy adults. .The trials, expected to enroll 30,000 healthy adults, are being conducted in several cities in the U.S. After injected with the vaccine, participants are given a self-swab kit to be used in they develop an illness. The trials are conducted by Pfizer Corp for BioNTech, Inc.The vaccines do not contain the whole Coronavirus, or parts of the virus than can make people ill, according to the test’s informed consent form. (Credit Image: © Robin Rayne/ZUMA Wire)、クレジット:©Robin Rayne/ZUMA Wire/共同通信イメージズ

    商品コード: 2020082704667

  • 2020年08月25日
    Covid-19 Vaccine testing begins in U.S.

    August 25, 2020, Atlanta, GA, USA: Volunteers selected to participate in blind Phase 2 and 3 clinical trials for Covid-19 vaccines are injected with either a placebo saline solution or one of two vaccines being evaluated for safety, tolerability, immunogenicity and efficacy in protection against Covid-19 in healthy adults. .The trials, expected to enroll 30,000 healthy adults, are being conducted in several cities in the U.S. After injected with the vaccine, participants are given a self-swab kit to be used in they develop an illness. The trials are conducted by Pfizer Corp for BioNTech, Inc.The vaccines do not contain the whole Coronavirus, or parts of the virus than can make people ill, according to the test’s informed consent form. (Credit Image: © Robin Rayne/ZUMA Wire)、クレジット:©Robin Rayne/ZUMA Wire/共同通信イメージズ

    商品コード: 2020082704573

  • 2020年08月25日
    Covid-19 Vaccine testing begins in U.S.

    August 25, 2020, Atlanta, GA, USA: Volunteers selected to participate in blind Phase 2 and 3 clinical trials for Covid-19 vaccines are injected with either a placebo saline solution or one of two vaccines being evaluated for safety, tolerability, immunogenicity and efficacy in protection against Covid-19 in healthy adults. .The trials, expected to enroll 30,000 healthy adults, are being conducted in several cities in the U.S. After injected with the vaccine, participants are given a self-swab kit to be used in they develop an illness. The trials are conducted by Pfizer Corp for BioNTech, Inc.The vaccines do not contain the whole Coronavirus, or parts of the virus than can make people ill, according to the test’s informed consent form. (Credit Image: © Robin Rayne/ZUMA Wire)、クレジット:©Robin Rayne/ZUMA Wire/共同通信イメージズ

    商品コード: 2020082704582

  • 2020年08月25日
    Covid-19 Vaccine testing begins in U.S.

    August 25, 2020, Atlanta, GA, USA: Volunteers selected to participate in blind Phase 2 and 3 clinical trials for Covid-19 vaccines are injected with either a placebo saline solution or one of two vaccines being evaluated for safety, tolerability, immunogenicity and efficacy in protection against Covid-19 in healthy adults. .The trials, expected to enroll 30,000 healthy adults, are being conducted in several cities in the U.S. After injected with the vaccine, participants are given a self-swab kit to be used in they develop an illness. The trials are conducted by Pfizer Corp for BioNTech, Inc.The vaccines do not contain the whole Coronavirus, or parts of the virus than can make people ill, according to the test’s informed consent form. (Credit Image: © Robin Rayne/ZUMA Wire)、クレジット:©Robin Rayne/ZUMA Wire/共同通信イメージズ

    商品コード: 2020082700912

  • 2020年08月25日
    Covid-19 Vaccine testing begins in U.S.

    August 25, 2020, Atlanta, GA, USA: Volunteers selected to participate in blind Phase 2 and 3 clinical trials for Covid-19 vaccines are injected with either a placebo saline solution or one of two vaccines being evaluated for safety, tolerability, immunogenicity and efficacy in protection against Covid-19 in healthy adults. .The trials, expected to enroll 30,000 healthy adults, are being conducted in several cities in the U.S. After injected with the vaccine, participants are given a self-swab kit to be used in they develop an illness. The trials are conducted by Pfizer Corp for BioNTech, Inc.The vaccines do not contain the whole Coronavirus, or parts of the virus than can make people ill, according to the test’s informed consent form. (Credit Image: © Robin Rayne/ZUMA Wire)、クレジット:©Robin Rayne/ZUMA Wire/共同通信イメージズ

    商品コード: 2020082704652

  • 2020年08月25日
    Covid-19 Vaccine testing begins in U.S.

    August 25, 2020, Atlanta, GA, USA: Volunteers selected to participate in blind Phase 2 and 3 clinical trials for Covid-19 vaccines are injected with either a placebo saline solution or one of two vaccines being evaluated for safety, tolerability, immunogenicity and efficacy in protection against Covid-19 in healthy adults. .The trials, expected to enroll 30,000 healthy adults, are being conducted in several cities in the U.S. After injected with the vaccine, participants are given a self-swab kit to be used in they develop an illness. The trials are conducted by Pfizer Corp for BioNTech, Inc.The vaccines do not contain the whole Coronavirus, or parts of the virus than can make people ill, according to the test’s informed consent form. (Credit Image: © Robin Rayne/ZUMA Wire)、クレジット:©Robin Rayne/ZUMA Wire/共同通信イメージズ

    商品コード: 2020082704790

  • 2020年08月25日
    Covid-19 Vaccine testing begins in U.S.

    August 25, 2020, Atlanta, GA, USA: Volunteers selected to participate in blind Phase 2 and 3 clinical trials for Covid-19 vaccines are injected with either a placebo saline solution or one of two vaccines being evaluated for safety, tolerability, immunogenicity and efficacy in protection against Covid-19 in healthy adults. .The trials, expected to enroll 30,000 healthy adults, are being conducted in several cities in the U.S. After injected with the vaccine, participants are given a self-swab kit to be used in they develop an illness. The trials are conducted by Pfizer Corp for BioNTech, Inc.The vaccines do not contain the whole Coronavirus, or parts of the virus than can make people ill, according to the test’s informed consent form. (Credit Image: © Robin Rayne/ZUMA Wire)、クレジット:©Robin Rayne/ZUMA Wire/共同通信イメージズ

    商品コード: 2020082704788

  • 2020年08月25日
    Covid-19 Vaccine testing begins in U.S.

    August 25, 2020, Atlanta, GA, USA: Volunteers selected to participate in blind Phase 2 and 3 clinical trials for Covid-19 vaccines are injected with either a placebo saline solution or one of two vaccines being evaluated for safety, tolerability, immunogenicity and efficacy in protection against Covid-19 in healthy adults. .The trials, expected to enroll 30,000 healthy adults, are being conducted in several cities in the U.S. After injected with the vaccine, participants are given a self-swab kit to be used in they develop an illness. The trials are conducted by Pfizer Corp for BioNTech, Inc.The vaccines do not contain the whole Coronavirus, or parts of the virus than can make people ill, according to the test’s informed consent form. (Credit Image: © Robin Rayne/ZUMA Wire)、クレジット:©Robin Rayne/ZUMA Wire/共同通信イメージズ

    商品コード: 2020082700939

  • 2020年08月25日
    Pfizer Claims 90 Percent Efficiency with COVID-19 Vaccine

    August 25, 2020, Atlanta, GA, USA: Volunteers selected to participate in blind Phase 2 and 3 clinical trials for Covid-19 vaccines are injected with either a placebo saline solution or one of two vaccines being evaluated for safety, tolerability, immunogenicity and efficacy in protection against Covid-19 in healthy adults. .The trials, expected to enroll 30,000 healthy adults, are being conducted in several cities in the U.S. After injected with the vaccine, participants are given a self-swab kit to be used in they develop an illness. The trials are conducted by Pfizer Corp for BioNTech, Inc.The vaccines do not contain the whole Coronavirus, or parts of the virus than can make people ill, according to the test’s informed consent form. (Credit Image: © Robin Rayne/ZUMA Wire)、クレジット:©Robin Rayne/ZUMA Wire/共同通信イメージズ

    商品コード: 2020111007796

  • 2020年08月25日
    Covid-19 Vaccine testing begins in U.S.

    August 25, 2020, Atlanta, GA, USA: Volunteers selected to participate in blind Phase 2 and 3 clinical trials for Covid-19 vaccines are injected with either a placebo saline solution or one of two vaccines being evaluated for safety, tolerability, immunogenicity and efficacy in protection against Covid-19 in healthy adults. .The trials, expected to enroll 30,000 healthy adults, are being conducted in several cities in the U.S. After injected with the vaccine, participants are given a self-swab kit to be used in they develop an illness. The trials are conducted by Pfizer Corp for BioNTech, Inc.The vaccines do not contain the whole Coronavirus, or parts of the virus than can make people ill, according to the test’s informed consent form. (Credit Image: © Robin Rayne/ZUMA Wire)、クレジット:©Robin Rayne/ZUMA Wire/共同通信イメージズ

    商品コード: 2020082704999

  • 2020年10月28日
    Operation Warp Speed

    October 28, 2020 - Joint Base San Antonio-Lackland, Texas, USA - Alejandra Ornelas, Operation Warp Speed research pharmacy technician, documents and verifies whether a patient receives a vaccine or placebo, Oct. 28, 2020, at Joint Base San Antonio-Lackland, Texas. The U.S. Food and Drug Administration authorized the restart of AstraZeneca‘s Phase 3 clinical trial, Oct. 26, 2020. (Credit Image: © U.S. Air Force/ZUMA Wire/ZUMAPRESS.com)、クレジット:©U.S. Air Force/ZUMA Wire/ZUMAPRESS.com/共同通信イメージズ

    商品コード: 2020111401405

  • 2020年10月28日
    Operation Warp Speed

    October 28, 2020 - Joint Base San Antonio-Lackland, Texas, USA - Alejandra Ornelas, Operation Warp Speed research pharmacy technician, documents and verifies whether a patient receives a vaccine or placebo, Oct. 28, 2020, at Joint Base San Antonio-Lackland, Texas. The U.S. Food and Drug Administration authorized the restart of AstraZenecas Phase 3 clinical trial, Oct. 26, 2020. (Credit Image: © U.S. Air Force/ZUMA Wire/ZUMAPRESS.com)、クレジット:©U.S. Air Force/ZUMA Wire/ZUMAPRESS.com/共同通信イメージズ

    商品コード: 2020112606181

  • 2020年11月16日
    LABORATORIO MODERNA THAT ITS VACCINE AGAINST COVID-19 IS ALMOST 95% EFFECTIVE.

    キーワード:新型コロナウイルス、ワクチン、開発、モデルナ、アメリカ、製薬会社、製薬企業-November 16, 2020: RIO DE JANEIRO, RJ, 16.11.2020 - LABORATORIO MODERNA THAT ITS VACCINE AGAINST COVID-19 IS ALMOST 95% EFFECTIVE - Preliminary studies released on Monday morning (16) show that Moderna‘s potential vaccine against Covid-19 is about 94.5% effective in preventing the new coronavirus. The immunizer is in the third phase of clinical tests, the last before the approval of regulatory agencies to be applied to the population. (Credit Image: © Saulo Angelo/TheNEWS2 via ZUMA Wire)、クレジット:©Saulo Angelo/TheNEWS2 via ZUMA Wire/共同通信イメージズ

    商品コード: 2020111800151

  • 2020年11月29日
    Pfizer Succesfully Concludes COVID-19 Vaccine study

    November 29, 2020, Canton, GA, USA: A volunteer Covid-19 vaccine tester walks her dog with minimal side effects after two injections weeks apart two months ago. The vaccine study, administered for Pfizer, Inc. by research centers in a number of cities in the U.S., involved comparing an investigational (study) vaccine against a placebo (injection with no active ingredient) to see if the vaccine can prevent COVID-19. .Pfizer announced that, after conducting the final efficacy analysis in their ongoing Phase 3 study, their mRNA-based COVID-19 vaccine candidate, BNT162b2, met all of the studyテ不 primary efficacy endpoints, and seeks FDA approval to release the vaccine to the public. (Credit Image: © Robin Rayne/ZUMA Wire)、クレジット:©Robin Rayne/ZUMA Wire/共同通信イメージズ

    商品コード: 2020120302952

  • 2020年11月29日
    Pfizer Succesfully Concludes COVID-19 Vaccine study

    November 29, 2020, Canton, GA, USA: A volunteer Covid-19 vaccine tester walks her dog with minimal side effects after two injections weeks apart two months ago. The vaccine study, administered for Pfizer, Inc. by research centers in a number of cities in the U.S., involved comparing an investigational (study) vaccine against a placebo (injection with no active ingredient) to see if the vaccine can prevent COVID-19. .Pfizer announced that, after conducting the final efficacy analysis in their ongoing Phase 3 study, their mRNA-based COVID-19 vaccine candidate, BNT162b2, met all of the studyテ不 primary efficacy endpoints, and seeks FDA approval to release the vaccine to the public. (Credit Image: © Robin Rayne/ZUMA Wire)、クレジット:©Robin Rayne/ZUMA Wire/共同通信イメージズ

    商品コード: 2020120302986

  • 2020年11月29日
    Pfizer Succesfully Concludes COVID-19 Vaccine study

    November 29, 2020, Canton, GA, USA: A volunteer Covid-19 vaccine tester walks her dog with minimal side effects after two injections weeks apart two months ago. The vaccine study, administered for Pfizer, Inc. by research centers in a number of cities in the U.S., involved comparing an investigational (study) vaccine against a placebo (injection with no active ingredient) to see if the vaccine can prevent COVID-19. .Pfizer announced that, after conducting the final efficacy analysis in their ongoing Phase 3 study, their mRNA-based COVID-19 vaccine candidate, BNT162b2, met all of the studyテ不 primary efficacy endpoints, and seeks FDA approval to release the vaccine to the public. (Credit Image: © Robin Rayne/ZUMA Wire)、クレジット:©Robin Rayne/ZUMA Wire/共同通信イメージズ

    商品コード: 2020120302630

  • 2021年05月18日
    American Life, Politics, and Economy

    May 18, 2021, New York, New York, USA: Sarasota, Florida. Although there are numerous FDA-approved treatments on the market, experts say many patients are turning to cannabis products containing THC and/or CBD, an ingredient of cannabis that is not psychoactive, to treat their migraines. The goal is to enroll 90 participants who will be randomized one each with THC, CBD, and a placebo. To qualify for the clinical trial, patients must experience migraines every month, must not be a regular cannabis user or use opioids, and must be age 21-65. (Credit Image: © John Marshall Mantel/ZUMA Wire)、クレジット:©John Marshall Mantel/ZUMA Wire/共同通信イメージズ

    商品コード: 2021052007971

  • 2021年05月18日
    American Life, Politics, and Economy

    May 18, 2021, New York, New York, USA: Sarasota, Florida. Although there are numerous FDA-approved treatments on the market, experts say many patients are turning to cannabis products containing THC and/or CBD, an ingredient of cannabis that is not psychoactive, to treat their migraines. The goal is to enroll 90 participants who will be randomized one each with THC, CBD, and a placebo. To qualify for the clinical trial, patients must experience migraines every month, must not be a regular cannabis user or use opioids, and must be age 21-65. (Credit Image: © John Marshall Mantel/ZUMA Wire)、クレジット:©John Marshall Mantel/ZUMA Wire/共同通信イメージズ

    商品コード: 2021052008198

  • 2021年05月18日
    American Life, Politics, and Economy

    May 18, 2021, New York, New York, USA: Sarasota, Florida. Although there are numerous FDA-approved treatments on the market, experts say many patients are turning to cannabis products containing THC and/or CBD, an ingredient of cannabis that is not psychoactive, to treat their migraines. The goal is to enroll 90 participants who will be randomized one each with THC, CBD, and a placebo. To qualify for the clinical trial, patients must experience migraines every month, must not be a regular cannabis user or use opioids, and must be age 21-65. (Credit Image: © John Marshall Mantel/ZUMA Wire)、クレジット:©John Marshall Mantel/ZUMA Wire/共同通信イメージズ

    商品コード: 2021052008124

  • 2021年05月18日
    American Life, Politics, and Economy

    May 18, 2021, New York, New York, USA: Sarasota, Florida. Although there are numerous FDA-approved treatments on the market, experts say many patients are turning to cannabis products containing THC and/or CBD, an ingredient of cannabis that is not psychoactive, to treat their migraines. The goal is to enroll 90 participants who will be randomized one each with THC, CBD, and a placebo. To qualify for the clinical trial, patients must experience migraines every month, must not be a regular cannabis user or use opioids, and must be age 21-65. (Credit Image: © John Marshall Mantel/ZUMA Wire)、クレジット:©John Marshall Mantel/ZUMA Wire/共同通信イメージズ

    商品コード: 2021052007991

  • 2021年06月17日
    Wild Animals: Florida Life and Economy

    June 16, 2021, SARASOTA, FLORIDA, USA: A study of 165 people tested two prescription drugs, varenicline, for smoking addiction, and naltrexone a drug used to treat alcoholism. Participants who received varenicline plus placebo had a higher smoking quit rate than those who were given varenicline and naltrexone. (Credit Image: © John Marshall Mantel/ZUMA Wire)、クレジット:©John Marshall Mantel/ZUMA Wire/共同通信イメージズ

    商品コード: 2021061809294

  • 2022年02月07日
    新型コロナウイルス治療薬の試験結果速報について会見する塩野義製薬

    塩野義製薬は7日、開発中の新型コロナウイルス感染症治療薬について、臨床試験のうち初期第2相の結果を発表した。プラセボ(偽薬)と比べて感染性のあるウイルス量(ウイルス力価)やウイルスのリボ核酸(RNA)量が減少。投与に伴う有害事象は軽微で、一定の安全性も確認した。来週に後期第2相の結果も出る予定で、同様に効果と安全性が確認できれば、来週か再来週にも承認申請に移る。臨床試験では1日1回、5日間の経口投与を行った。ウイルス力価が陰性になるまでの期間の中央値がプラセボと比べ2日短縮できた。軽症・中等症患者向けに2月中に40万―50万人分、3月末までに100万人分の供給が可能。日本人に飲みやすい小さめの錠剤で国内需要を見込む。手代木功社長は「国とは新型コロナウイルス感染症に悩む社会を何とかしたいと前向きな議論ができている」と手応えを語った。さらに国際的な第3相試験も進め、今夏にデータが明らかになる予定。写真は会見する手代木社長。=2022(令和4)年2月7日、東京都内、クレジット:日刊工業新聞/共同通信イメージズ

    商品コード: 2022022409653

  • 1